Nine Diagnostics and Orbits Oncology Launch Exploratory Partnership on Precision Oncology Platform
Nine Diagnostics and Orbits Oncology have entered into an exploratory partnership to jointly develop a next-generation precision oncology diagnostics platform. The collaboration pairs Nine Diagnostics’ nanosensor-based molecular fingerprinting, which captures systemic disease signals from blood, with Orbits’ AI-powered computer vision platform that analyzes patient-derived organoid microscope imagery to provide a more dynamic and clinically relevant picture of treatment response.
Nanosensor Liquid Biopsy Detects and Classifies Brain Tumors — Nature Nanotechnology
Nine Diagnostics co-founders Daniel A. Heller, PhD, and Mijin Kim, PhD, co-authored a cover article in Nature Nanotechnology (February 2026) demonstrating 98% accuracy in brain tumor detection and 71% accuracy in tumor type identification across 739 patients at Memorial Sloan Kettering Cancer Center, Northwestern University, and NYU. The study established the first multi-site clinical validation of quantum-defect-modified SWCNT arrays for cancer liquid biopsy, using a machine perception approach that detects tumors indirectly through the body’s systemic molecular response rather than requiring tumor material to cross the blood-brain barrier.
Nine Diagnostics Graduates from ACS BrightEdge Entrepreneurs Program
Nine Diagnostics graduated from the American Cancer Society BrightEdge Entrepreneurs Program, culminating in a Demo Day pitch presentation of the Nine Diagnostics nanosensor-enabled, machine learning-driven diagnostic platform. The 10-month program, run by BrightEdge, ACS’s impact investment and innovation arm, provided structured mentorship on scientific strategy, clinical translation, and early go-to-market planning, alongside access to oncology thought leaders and investors. Graduation marks a key milestone in Nine Diagnostics’ development, reinforcing the relevance of its platform and momentum toward clinical validation and deployment.
Daniel Heller Featured on KVIA-TV ABC-7 for Nanosensor Ovarian Cancer Detection Research
Nine Diagnostics co-founder Daniel A. Heller, PhD, was featured on KVIA-TV ABC-7 News El Paso in October 2025 for his work developing a nanosensor-based liquid biopsy for early ovarian cancer detection, funded by the Ovarian Cancer Research Alliance in partnership with Microsoft’s AI for Good Lab. Reporter Marcel Clarke’s segment, “Nanotech Aims to Catch Ovarian Cancer Early,” covers the platform’s potential to detect ovarian cancer at stages one and two from blood alone.
Nine Diagnostics Selected for Medical Alley Q3 Innovation Showcase
Nine Diagnostics presented at the Q3 Medical Alley Innovation Showcase on September 22, 2025, one of six companies selected to present within Minnesota’s health innovation ecosystem, one of the most concentrated healthcare networks in the country. The selection connected Nine Diagnostics with venture capital firms, strategic partners, and family offices actively investing in the next generation of health technology.
Nine Diagnostics Wins Runner-Up at RESI Boston Longevity Competition
Nine Diagnostics placed second in the Longevity Global Pitch Competition at RESI Boston on September 17, 2025, part of a newly launched longevity and aging track organized by Life Science Nation in partnership with The Engine. The recognition included a one-year Flex-Residency at The Engine and reflects growing interest from the longevity investment community in Nine Diagnostics’ multi-omic nanosensor platform.
Nine Diagnostics Co-Founder Daniel Heller in Women’s Health Magazine
Nine Diagnostics co-founder Dr. Daniel Heller was featured in Women’s Health Magazine discussing why ovarian cancer remains so difficult to detect early and how AI-enabled nanosensor technology is changing that story. His research uses carbon nanotube nanosensors and AI to identify molecular fingerprints in blood that already outperform CA-125, today’s primary but unreliable ovarian cancer biomarker. The coverage underscores the clinical urgency and scientific promise driving Nine Diagnostics’ platform.
Building a Measurement Science Startup — Applied Spectroscopy Practica
Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics, co-authored a paper in Applied Spectroscopy Practica presenting a framework for translating measurement science into healthcare products, drawn from his contribution to a SciX LI symposium on commercializing academically developed analytical technologies. The paper addresses the practical challenges of building a measurement science startup — from problem definition and product-market fit to leveraging innovation ecosystems — and defines how scientific co-founders can best contribute as their company evolves.
Nine Diagnostics CEO Freddy Nguyen Named 2025 National Academy of Medicine Scholar in Diagnostics
Nine Diagnostics co-founder and CEO Dr. Freddy T. Nguyen has been named a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine, recognizing leaders advancing diagnostic quality, safety, and equity. As a Scholar, Dr. Nguyen will advance a patient-centered framework for diagnostic technology development, addressing bias, validation, and clinical implementation of next-generation tools. The recognition reflects Nine Diagnostics’ commitment to ensuring diagnostic innovation is both scientifically rigorous and broadly impactful.
Nine Diagnostics CEO Freddy Nguyen at MIT Health Science Forum 2025
Nine Diagnostics CEO Dr. Freddy Nguyen delivered an MIT Startup Exchange Lightning Talk at the 2025 MIT Health Science Forum, hosted by the MIT Industrial Liaison Program, an event convening researchers, global industry leaders, and select startups advancing transformative healthcare. His talk, “Determining Treatment Effectiveness, Discovering New Biology Using AI-Enabled Nanosensor Technology,” highlighted Nine Diagnostics’ nanosensor and AI platform for treatment monitoring and biomarker discovery, reflecting the company’s growing recognition within the MIT innovation ecosystem and broader life sciences community.